Skip to main content

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Análisis de la cuasispecie viral en la infección por virus de la hepatitis B: evolución natural yu asociada al tratamiento antiviral

IP: -
Collaborators: Maria Buti Ferret, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI09/00899
Duration: 01/01/2010 - 31/12/2012

Caracterización de perfiles proteómicos predictivos de hepatotoxicidad asociada a medicamentos antituberculosos: un estudio exploratorio

IP: -
Collaborators: Jaume Reventós Puigjaner, Francesc Canals Suris, Maria Buti Ferret, Xavier Martínez Gómez, Teresa Soriano Sánchez, Israel Molina Romero, Eulàlia Pérez Esquirol, Mònica Sabaté Gallego, Maria Urquizu Padilla, Núria Colome Calls
Funding agency: Instituto de Salud Carlos III
Funding: 150645
Reference: EC08/00250
Duration: 01/01/2009 - 31/12/2012

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Variabilidad de la región codificante de la proteina de la capsida viral del virus de la hepatitis B y su relación con el curso de la infección y la respuesta a tratamiento antivirales

IP: -
Collaborators: Maria Buti Ferret
Funding agency: Instituto de Salud Carlos III
Funding: 56265
Reference: PI061512
Duration: 01/01/2007 - 30/12/2009

Related news

The meetings served to share advances in translational research and consolidate international scientific alliances in the study of liver diseases

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Diego Yeste Fernandez

Diego Yeste Fernandez

Senior researcher
Growth and Development
Read more
Juan Martin Dupraz

Juan Martin Dupraz

P Management and Admin. Project manager
Business Development Unit
Innovation and Technology Transfer Directorate
Read more
Joan Castell Conesa

Joan Castell Conesa

Molecular Medical Imaging
Read more
Raquel Mena Marcos

Raquel Mena Marcos

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.